LegoChem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 11, 2023 at 01:16 pm IST
Share
LegoChem Biosciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 12,081.4 million compared to KRW 11,704.34 million a year ago. Net loss was KRW 20,040.83 million compared to KRW 7,813.91 million a year ago. Basic loss per share from continuing operations was KRW 760 compared to KRW 322 a year ago. Diluted loss per share from continuing operations was KRW 760 compared to KRW 322 a year ago. Basic loss per share was KRW 760 compared to KRW 322 a year ago.
For the six months, sales was KRW 0.00028 million compared to KRW 0.00048 million a year ago. Net loss was KRW 37,786.79 million compared to KRW 16,315.97 million a year ago. Basic loss per share from continuing operations was KRW 1,433 compared to KRW 672 a year ago. Diluted loss per share from continuing operations was KRW 1,433 compared to KRW 672 a year ago. Basic loss per share was KRW 1,433 compared to KRW 672 a year ago.
LigaChem Biosciences Inc, formerly LegoChem Biosciences Inc, is a Korea-based biotechnology company mainly engaged in development and discovery of new pharmaceuticals based on medical chemistry. The Company principally involves in the development of new drugs, including antibiotics, anticoagulants, anticancer, antiplatelet, anti-inflammatory, as well as antibody-drug-conjugates (ADC), among others. The Company provides technology transfer, joint and contact research and research services. In addition, the Company sells pharmaceutical products.